<DOC>
	<DOCNO>NCT00115219</DOCNO>
	<brief_summary>The purpose study objective evaluate efficacy safety etanercept 50 mg BIW RA subject show sub-optimal response standard dose etanercept ( 50 mg QW ) concomitant methotrexate therapy .</brief_summary>
	<brief_title>Evaluating Efficacy Safety Etanercept 50 mg Twice Weekly ( BIW ) Rheumatoid Arthritis ( RA ) Subjects Who Are Sub-Optimal Responders Etanercept 50 mg Once Weekly ( QW )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis RA disease duration &gt; 6 month Current prior continuous etanercept ( 50 mg weekly ) treatment least 5 month prior screen Subjects must receive methotrexate ( MTX ) stable dose &gt; 15 mg/week least 4 week prior screen Suboptimal response etanercept define presence follow criterion ( base 28 joint count ) screening : 5 swollen joint 5 tender joint Subjects currently receive oral corticosteroid must dose equivalent prednisone less equal 10 mg/day screen Subjects currently receive nonsteroidal antiinflammatory drug ( NSAIDs ) , must stable dose least 2 week prior screen Subjects currently receive DMARD therapy ( include sulfasalazine , hydroxychloroquine leflunomide ) , must stable dose least 4 week prior screen Nursing mother , female subject plan become pregnant , male subject plan pregnancy spouse/partner study ACR functional class IV Receipt investigational drug biologic within 4 week study drug initiation Concurrent history psychiatric disease would interfere ability comply study protocol give informed consent History alcohol drug abuse within 12 month screen visit Severe comorbidities include : History cancer ( resect cutaneous basal squamous cell carcinoma , situ cervical cancer ) within 5 year screen visit . Documentation diseasefree state since treatment require ; Diagnosis Class III IV congestive heart failure ( CHF ) myocardial infarction ( MI ) within 12 month screen ; Unstable stable angina pectoris ; Uncontrolled hypertension ( define systolic blood pressure measurement great 180 mm Hg diastolic blood pressure great 110 mm Hg ) ; Oxygendependent pulmonary disease ; Known HIVpositive status immunodeficiency syndrome ; Chronic hepatitis B ( HbsAg ) C ( HCV ) ; Systemic lupus erythematosus ( SLE ) ; CNS demyelinate event suggestive multiple sclerosis ; Presence active infection underlying disease could predispose subject infection ( e.g. , history recurrent infection , nonhealing leg ulcer , advance poorly control diabetes ) ; Active prior history tuberculosis ( know exposure ) . Concurrent treatment cyclophosphamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rheumatoid Arthritis , RA</keyword>
	<keyword>EnbrelÂ® ( etanercept )</keyword>
	<keyword>Clinical Trials , Amgen</keyword>
	<keyword>Immunex , Methotrexate ( MTX )</keyword>
	<keyword>Rheumatoid Arthritis ( RA )</keyword>
</DOC>